Literature DB >> 1152343

[Dosage and elimination of Dextran 40 in patients on hemodialysis (author's transl)].

H Köhler, T R Weihrauch, P Fiegel, W Kirch, D Höffler.   

Abstract

In 24 patients on regular hemodialysis the serum levels and the half-life of dextran 40 were determined after single or repeated infusion of dextran 40 (Rheomacrodex¿). One group of hemodialysis trainees had a dextran 40 half-life of 2237 +/- 447 min. In contrast, a second group, consisting of hospital dialysis patients, had a dextran 40 half-life of 4283 +/- 510 min, whereas patients with normal renal function had a half-life of 573 +/- 183 min. The difference in dextran half-life between the two groups of hemodialysis patients may be explained by the better residual renal function of our hemodialysis trainees. During hemodialysis no change in serum dextran levels could be observed. Intermitten hemodialysis, also, had no influence on the exponential elimination of dextran over a period of 6.25 days. Since hemodialysis by itself has no effect upon dextran elimination, the dosage fo dextran 40 has to be adjucted to the prolonged elimination time only, disregarding dialysis. After the fourth infusion of 50 g dextran 40 (twice a week 500 ml of 10% dextran 40) serum dextran levels exceeding 50 g/l and cutaneous bleeding were observed. To avoid these complications an initial saturation dose is suggested, followed by a maintenance dose adjusted to the impaired renal function.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1152343     DOI: 10.1007/bf01468757

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  12 in total

1.  FURTHER STUDIES ON THE EFFECT OF DEXTRAN OF VARIOUS MOLECULAR WEIGHT ON THE COAGULATION MECHANISM.

Authors:  I M NILSSON; O EIKEN
Journal:  Thromb Diath Haemorrh       Date:  1964-04-15

2.  Gastro-intestinal excretion of dextran-C14.

Authors:  B ABERG; W L BLOOM; E HANSSON
Journal:  Acta Physiol Scand       Date:  1961-06

3.  COATING OF VASCULAR SURFACES AND CELLS. A NEW CONCEPT IN PREVENTION OF INTRAVASCULAR THROMBOSIS.

Authors:  W L BLOOM; D S HARMER; M F BRYANT; S S BREWER
Journal:  Proc Soc Exp Biol Med       Date:  1964-02

4.  THE RENAL CLEARANCE OF DEXTRAN OF DIFFERENT MOLECULAR SIZES IN NORMAL HUMANS.

Authors:  G ARTURSON; G WALLENIUS
Journal:  Scand J Clin Lab Invest       Date:  1964       Impact factor: 1.713

5.  Adsorption of carbon-14 dextran to human blood platelets and red blood cells, in vitro.

Authors:  S ROTHMAN; E ADELSON; A SCHWEBEL; R D LANGDELL
Journal:  Vox Sang       Date:  1957-03       Impact factor: 2.144

6.  [Subcutaneous arteriovenous shunts for hemodialysis and extracorporeal blood irradiation. Experiences in 105 anastomoses].

Authors:  T Junginger; F Spelsberg; H Pichlmaier; H J Gurland; W Klinger
Journal:  Dtsch Med Wochenschr       Date:  1972-02-18       Impact factor: 0.628

7.  Further studies on the platelet-inhibitory effect of guanidinosuccinic acid and its role in uremic bleeding.

Authors:  H I Horowitz; I M Stein; B D Cohen; J G White
Journal:  Am J Med       Date:  1970-09       Impact factor: 4.965

8.  Platelet function in renal failure.

Authors:  G Eknoyan; S J Wacksman; H I Glueck; J J Will
Journal:  N Engl J Med       Date:  1969-03-27       Impact factor: 91.245

9.  [Quantitative micro determination of dextran. I. In body fluids].

Authors:  W Appel; V Wirmer; D Sprengard
Journal:  Z Klin Chem Klin Biochem       Date:  1968-09

10.  [Studies on the fate of injected dextran in the guinea pig].

Authors:  K H Ebert; G Schenk; R Scholz
Journal:  Z Klin Chem Klin Biochem       Date:  1968-09
View more
  4 in total

1.  [The elimination of hydroxyethyl starch 200/0.5, dextran 40 and oxypolygelatine (author's transl)].

Authors:  H Köhler; H Zschiedrich; A Linfante; F Appel; H Pitz; R Clasen
Journal:  Klin Wochenschr       Date:  1982-03

2.  Elimination of hexamethylene diisocyanate cross-linked polypeptides in patients with normal or impaired renal function.

Authors:  H Köhler; W Kirch; P Fuchs; K Stalder; A Distler
Journal:  Eur J Clin Pharmacol       Date:  1978-12-18       Impact factor: 2.953

3.  [Prophylaxis and therapy of shunt thrombosis in terminal renal insufficiency (author's transl)].

Authors:  H Köhler
Journal:  Klin Wochenschr       Date:  1977-01-15

Review 4.  Clinical pharmacokinetic considerations in the use of plasma expanders.

Authors:  U Klotz; H Kroemer
Journal:  Clin Pharmacokinet       Date:  1987-02       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.